Non-immunogenic staphylokinase in the treatment of high-risk massive pulmonary embolism in the early postoperative period due to femoral fragment wound

A case report of double thrombolytic therapy with non-immunogenic staphylokinase at a dose of 15 mg bolus over 15 s in a patient with a high-risk massive pulmonary embolism (PE) in the early postoperative period due to femoral wound is described. After the second thrombolysis, a decrease in the pulmonary arteries thrombotic lesions according to multislice computed tomography data, restoration of right ventricular function, and a decrease in pulmonary hypertension were observed. Reuse of the non-immunogenic staphylokinase did not lead to the major bleeding and hemorrhagic stroke, did not provoke a drop in hemoglobin and did not require blood transfusion. Upon discharge of the patient, normalization of the general blood test parameters was noted: the level of hemoglobin increased from 86 to 112 g/l, erythrocytes — from 2.8 to 3.5x1012/l, hematocrit — from 26 to 32%. Thus, non-immunogenic staphylokinase has demonstrated high efficacy and safety in the treatment of patient with a high-risk massive PE in the early postoperative period.

1. Markov VA, Duplyakov DV, Konstantinov SL, et al. Advanced results of Fortelyzin® use in the FRIDOM1 study and real clinical practice. Russian Journal of Cardiology. 2022;27(8):5178 (In Russ.) DOI:10.15829/1560-4071-2022-5178.

2. Markov VA, Duplyakov DV, Konstantinov SL, et al. Fortelyzin® in comparison with Metalyse® for ST-elevated myocardial infarction: one-year results and clinical outcomes of a multicenter randomized study FRIDOM1. Russian Journal of Cardiology. 2018;(11):110-116 (In Russ.) DOI:10.15829/1560-4071-2018-11-110-116.

3. Gusev EI, Martynov MYu, Nikonov AA, et al.; FRIDA Study Group. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4,5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. Lancet Neurol. 2021;20(9):721-728. DOI:10.1016/S1474-4422(21)00210-6.

4. Gusev EI, Martynov MY, Shamalov NA, et al. Nonimmunogenic staphylokinase in the treatment of acute ischemic stroke (FRIDA trial results). Zhurnal Nevrologii i sikhiatriiI m S S Korsakova. 2022;122(7):56-65 (In Russ.) DOI:10.17116/jnevro202212207156.

5. Kirienko AI, Yarovaya EB, Kutsenko VA, et al. Non-Immunogenic Staphylokinase vs Alteplase in Patients with Massive Pulmonary Embolism: the Protocol of a Multiple-Center Open-Label Randomized Trial FORPE. Flebologiya. 2022;16(2):114-121 (In Russ.) DOI:10.17116/flebo202216021114.

6. Konstantinides SV, Meyer G, Becattini C, et al.; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020; 41(4):543-603. DOI:10.1093/eurheartj/ehz405.

7. Russian guidelines for the diagnosis, treatment and prevention of venous thromboembolic complications. Flebologiya. 2015;4(2):1-52 (In Russ.)

8. Konstantinides SV, Barco S, Lankeit M, et al. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016;67(8):976-990. DOI:10.1016/j.jacc.2015.11.061.